Decipher Genomic Testing Enables Personalized Treatment Planning for Urologic Cancers
At Veracyte, we are dedicated to the continued pursuit of evidence for our Decipher genomic tests, which help in making treatment decisions for prostate and bladder cancers.
Decipher is the Most Validated Tissue-based Gene Expression Test in Prostate Cancer
Learn More:
Decipher Prostate is a tissue-based genomic test that provides actionable information for treatment decision-making across the spectrum of localized prostate cancer.
Decipher Bladder is the only commercially available genomic subtyping tool for patients with bladder cancer to help inform key treatment decisions.
Sunday, May 26, 2024
Decipher genomic classifier shows prognostic value in intermediate-risk prostate cancer
Monday, May 06, 2024
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
Monday, April 22, 2024
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Tuesday, April 16, 2024
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Tuesday, February 27, 2024
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Monday, May 06, 2024
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
Monday, April 22, 2024
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Tuesday, April 16, 2024
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Tuesday, February 27, 2024
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
August 7, 2024
2024 Collaborative Urology Research Symposium (CUReS)
August 9 – 10, 2024
Louisiana Urological Society
August 23, 2024
7th Annual Oklahoma Urologic Symposium
August 28, 2024
San Diego Urological Society
September 5 – 8, 2024
Georgia Urological Society
September 5, 2024
New England AUA
September 5, 2024
82nd Annual Meeting – Mid Atlantic Section of the AUA
September 13, 2024
North Carolina Urological Association
September 13 – 14, 2024
Solaris 2024
September 15 – 17, 2024
Digital Diagnostic Summit
September 16 – 17, 2024
Vanderbilt Urology Society
September 18, 2024
North Central Section AUA
September 19, 2024
Northeastern Section AUA
September 20 – 22, 2024
Innovations in Urologic Practice
September 20, 2024
2nd Annual APCF Prostate Cancer Symposium
September 22, 2024
NYC Prostate Cancer Summit
September 27, 2024
Ellis Fischel Clinical Cancer Symposium
September 29, 2024
ASTRO
October 4 – 6, 2024
2024 Alabama Urology Network (AUN)
October 10, 2024
UroGPO National APP Summit: East
October 17, 2024
Southwest Prostate Cancer Symposium
October 27, 2024
Western Section of the AUA
October 30, 2024
South Central AUA